Fortress Biotech Reports Q3 Revenue of $19 Million, Outlines Growth Path for Dermatology Portfolio
Fortress Biotech posted $19 million in third-quarter 2026 revenue while highlighting clinical and commercial progress for its dermatology treatments.
🏢CompaniesPhoto: Motley Fool
Key points
- Reported $19 million in total revenue for the third quarter of 2026.
- Emrosi achieved a 30% clear-skin rate in clinical trials compared to 12.8% for Oracea.
- Commercial insurance coverage reached 40% of target market lives.
Fortress Biotech generated $19 million in total revenue during the third quarter of 2026, according to details shared by management on November 12, 2026. For everyday investors tracking the pharmaceutical sector, the company's financial trajectory hinges heavily on prescription volume and insurance coverage expansion for its core dermatology products to achieve sustained positive cash flow.
Clinical trial results for the rosacea treatment Emrosi showed that 30% of patients achieved clear skin, outperforming a competing drug, Oracea, which recorded 12.8%. Management noted that higher symptom clearance rates tend to drive prescription refills because fully cleared patients remain symptom-free for longer periods.
On the commercial front, insurance coverage has expanded to reach 40% of target market lives, minimizing patient step-edits and allowing the company to secure higher net prices per prescription. Additionally, the firm posted positive non-GAAP adjusted EBITDA, aided by reduced manufacturing costs for its primary medication and despite absorbing a one-time $1.7 million vendor dispute settlement.
What to watch next: Investors should monitor ongoing prescriber adoption and further additions to health plan formularies to gauge pricing discipline and sales momentum.
Source Motley Fool — fool.com/earnings/takeaways/2026/11/13/fortress-biotech-3-key-takea… ↗
Read next
🧠AI AnalysisCredo Technology Shares Fall Sharply Following September Earnings Report
Credo stock has declined 32% since its September 1 earnings release, trading significantly lower than its June record high.
🧠AI AnalysisArtificial Intelligence Dominates Market Focus Once Again
Market attention remains anchored entirely on the artificial intelligence sector as alternative topics take a back seat for another consecutive week.
🧠AI AnalysisNvidia Shares Slide as CEO Jensen Huang Resigns Following Scandal
Nvidia's market capitalization dropped to $3.93 trillion after co-founder Jensen Huang resigned following revelations of personal misconduct.
🧠AI AnalysisEmbraer Maintains Buy Rating Following Third-Quarter Performance
An independent analyst has reaffirmed a buy rating on Embraer shares following the release of the company's third-quarter financial results.
🧠AI AnalysisAnthropic Targets $1.4 Trillion Valuation in Upcoming Nasdaq Debut
AI developer Anthropic is set to list on the Nasdaq with a price range of $70 to $78 per share, potentially valuing the company at $1.4 trillion.
🧠AI AnalysisLowe's Positioned for Growth Amid Expanding Home Remodeling Budgets
An analysis of Lowe's Companies suggests the home improvement retailer is well-positioned to capitalize on increasing consumer spending in the remodeling sector.